lupus nephritis
Conditions
Interventions
Tetaticept treatment Group:N/A
Sponsors
Fujian Provincial Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Adult patients, regardless of gender; 2. The diagnosis of systemic lupus erythematosus combined with lupus nephritis meets the criteria of the American College of Rheumatology; 3. The patient was diagnosed with lupus nephritis by biopsy, which was confirmed to meet the 2003 ISN/RPS standard of the International Society of Nephrology/Society of Renal Pathology. 4. Volunteer to participate in this study and sign informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients requiring dialysis or kidney transplantation; 2. Allergy to the study drug; 3. Received live vaccine within 30 days prior to baseline; 4. Women who are pregnant or planning to become pregnant recently, or lactating women; 5. Patients with active hepatitis or a history of severe liver disease or disease; 6. Patients with immune deficiency, uncontrolled severe infection, and active or recurrent gastrointestinal ulcers; 7. Subjects who are participating in clinical studies of other drugs; In addition to the above, the investigators determined that there were other reasons for ineligibility for this clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Urine protein;Creatinine; | — |
Secondary
| Measure | Time frame |
|---|---|
| Albumin;Complement C3;Complement C4;Anti-dsDNA;Anti-nuclear antibody;c reactive protein;erythrocyte sedimentation rate;IgG;IgM;IgA; | — |
Countries
China
Contacts
Public ContactFu-Yuan Hong
Fujian Provincial Hospital
Outcome results
None listed